anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

135,181-135,240 of 319,975

filter-aware
57
The diagram uses a central triangle to represent the entity, with arrows indicating capital inflows from IPO, private phase rollovers, and management investments.Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
58
Pershing Square Portfolio (multiple positions)Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
59
The slide provides a snapshot of the discount to NAV for PSH, including specific historical high/low/average discount data.Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
60
The chart shows the stock price (blue) consistently trading below the NAV (green).Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
61
The chart highlights a significant disparity between broker-traded and exchange-traded volumes, with a dashed line indicating the weekly average.Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
62
The slide highlights that broker trading volume is 2.2x exchange traded volume.Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
63
Pershing Square Portfolio (multiple positions)Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
64
Pershing Square Portfolio (multiple positions)Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
65
Pershing Square Portfolio (multiple positions)Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
66
Pershing Square Portfolio (multiple positions)Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
67
Pershing Square Portfolio (multiple positions)Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement1 hit
01
Slide 1
Minimalist slide with a single metric and company branding.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
02
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
03
The chart uses a timeline-based annotation style to correlate M&A activity with stock performance.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
04
The chart demonstrates long-term market mispricing of earnings growth potential.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
05
This slide provides a high-level company profile and performance summary.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
06
The chart uses callout boxes to correlate specific acquisition announcements with share price movements.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
07
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
08
The chart uses callouts to annotate specific events (IPO and acquisition announcement) that correlate with share price movements.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
09
Uses a diagnostic structure to debunk potential explanations for stock performance.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Problem1 hit
10
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Problem1 hit
11
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
12
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
13
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
14
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
15
The chart uses a 4,502% return figure to illustrate the ~45x growth mentioned in the action title.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
16
This slide outlines the core 'roll-up' strategy that defined Valeant's business model.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
17
The slide outlines the core pillars of Valeant's M&A success.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
18
Uses a qualitative scoring system represented by filled/partially filled circles.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
19
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
20
The table uses a low/mid/high scenario approach to calculate value creation based on multiples of 2014 Pro-Forma Free Cash Flow.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
21
The slide uses callout boxes to correlate specific corporate events with stock price movements.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
22
The chart illustrates the 'multiple expansion' of Valeant's stock relative to a fixed future earnings consensus.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain1 hit
23
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Agitate1 hit
24
The slide uses a torn-paper aesthetic for the quotes.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Agitate1 hit
25
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Agitate1 hit
26
The slide uses a 'However' transition to pivot from a standard valuation to a more complex, asset-based argument.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Solution1 hit
27
The slide uses a structured table format to justify valuation inputs for an acquisition model.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Solution1 hit
28
The table models four scenarios based on annual M&A spend ($0bn, $5bn, $10bn, $20bn).Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Solution1 hit
29
The table uses a weighted average approach (70% * 20.0x + 30% * 8.0x = 16.4x).Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Solution1 hit
30
The slide uses a 10% discount rate for PV calculations and assumes a constant 16x NTM P/E multiple.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Beat · Solution1 hit
31
Includes disclaimer regarding valuation assumptions and data sources.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
32
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
33
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
34
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
35
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
36
Uses 'X' icons to denote negative attributes of peer groups.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
37
The slide uses specific financial metrics (EBITA, Gross Margin, Forward EPS) to establish a peer benchmark for Valeant's portfolio durability.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
38
The table includes a calculated average row at the bottom.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
39
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
40
The slide justifies using non-healthcare benchmarks for valuation by highlighting similar margin and growth profiles.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
41
The slide uses a bar chart to establish a valuation benchmark for non-healthcare sectors.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
42
The chart uses a box-plot style to show ranges for different comparable categories.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
43
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
44
The slide uses a bridge framework to reconcile 2015 revenue to 2020 estimates for cliff products.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
45
The slide provides specific financial modeling parameters for Valeant and Salix, excluding future acquisitions.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
46
The slide details specific financial ratios (90% conversion, 4x leverage target, 5.75% cost of debt) and compares them to current/transaction-specific metrics.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
47
The slide details the logic for M&A spending caps and the subsequent use of excess debt capacity for share repurchases.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 1 hit
01
Slide 1
This is a formal letter formatted as a slide.Herbalife, Ltd. (HLF) · David Klafter
Shareholder letter Activist investor Beat · Hook1 hit
02
This is a formal letter/document page, not a typical presentation slide.Herbalife, Ltd. (HLF) · David Klafter
Shareholder letter Activist investor Beat · Complication1 hit